Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors

Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates

(2016) Ludovica Monti et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives

(2015) Srinivas Deekonda et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The design of multitarget ligands for chronic and neuropathic pain

(2015) Szabolcs Dvoracsko et al.   Future Medicinal Chemistry

Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner

(2015) Ferenc Zádor et al.   NEUROPHARMACOLOGY

Hypothalamic dopaminergic neurons in an animal model of seasonal affective disorder

(2015) Sean P. Deats et al.   NEUROSCIENCE LETTERS

Receptome: Interactions between three pain-related receptors or the “Triumvirate” of cannabinoid, opioid and TRPV1 receptors

(2015) Ferenc Zádor et al.   PHARMACOLOGICAL RESEARCH

Design, Synthesis and Biological Evaluation of Two Opioid Agonist and Cav2.2 Blocker Multitarget Ligands

(2014) Adriano Mollica et al.   Chemical Biology & Drug Design

New Orally Active Dual Enkephalinase Inhibitors (DENKIs) for Central and Peripheral Pain Treatment

(2014) Hervé Poras et al.   JOURNAL OF MEDICINAL CHEMISTRY

Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity

(2014) Ferenc Zádor et al.   NEUROCHEMISTRY INTERNATIONAL

Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results

(2014) Nadine Jagerovic et al.   Drug Design Development and Therapy

Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance

(2013) Morgan Le Naour et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain

(2013) Alexander T. Podolsky et al.   LIFE SCIENCES

Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal

(2013) J.L. Scavone et al.   NEUROSCIENCE

Orexigenic effects of endomorphin-2 (EM-2) related to decreased CRH gene expression and increased dopamine and norepinephrine activity in the hypothalamus

(2013) Luigi Brunetti et al.   PEPTIDES

Similarity maps - a visualization strategy for molecular fingerprints and machine-learning methods

(2013) Sereina Riniker et al.   Journal of Cheminformatics

Protein kinase C inhibitor BIM suspended TRPV1 effect on mu-opioid receptor

(2012) Mária Wollemann et al.   BRAIN RESEARCH BULLETIN

admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties

(2012) Feixiong Cheng et al.   Journal of Chemical Information and Modeling

Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors

(2012) Ferenc Zádor et al.   NEUROCHEMISTRY INTERNATIONAL

AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies

(2012) Kathryn A. Seely et al.   NEUROPHARMACOLOGY

Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs

(2010) Pradeep J. Nathan et al.   CNS Neuroscience & Therapeutics

Opioids and Cannabinoids Interactions: Involvement in Pain Management

(2010) Julie Desroches et al.   CURRENT DRUG TARGETS

Cellular Mechanisms Underlying the Interaction between Cannabinoid and Opioid System

(2010) D. Parolaro et al.   CURRENT DRUG TARGETS

Cannabinoid–opioid interactions during neuropathic pain and analgesia

(2009) Ittai Bushlin et al.   CURRENT OPINION IN PHARMACOLOGY

Pharmacological efficacy and safety profile of taranabant in preclinical species

(2009) T.M. Fong et al.   DRUG DEVELOPMENT RESEARCH

CB1 Receptor-Independent Actions of SR141716 on G-Protein Signaling: Coapplication with the  -Opioid Agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol Unmasks Novel, Pertussis Toxin-Insensitive Opioid Signaling in  -Opioid Receptor-Chinese Hamster Ovary Cells

(2009) R. Cinar et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats

(2008) P AZIZI et al.   BEHAVIOURAL BRAIN RESEARCH

The μ-opioid receptor agonist morphine, but not agonists at δ- or κ-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors

(2008) D da Fonseca Pacheco et al.   BRITISH JOURNAL OF PHARMACOLOGY

Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides

(2008) Romano Silvestri et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antiaversive Effects of Cannabinoids: Is the Periaqueductal Gray Involved?

(2008) F. A. Moreira et al.   NEURAL PLASTICITY